HONG KONG SAR – Media OutReach Newswire – December 8, 2023 – Hong Kong’s leading biomedical and microbiome technology company,
G-NiiB GenieBiome, is pleased to announce that a groundbreaking large-scale, randomized, double-blind, placebo-controlled clinical trial (“the Trial”) conducted on the efficacy of SIM01, an oral microbiome immunity formulation developed by a top medical school in Hong Kong, covering 463 COVID-19 patients, clearly proved that consumption of SIM01, an oral formula of microencapsulated live bacteria, could significantly improve the intestinal microbiota after six months and lead to remarkable relief of post-COVID-19 symptoms. after-effects (“long COVID”), encompassing a range of symptoms affecting different systems and organs. The findings of the trial were published yesterday in
Lancet infectious diseasesthe authoritative international medical journal on infectious diseases.
G-NiiB GenieBiome’s flagship product, G-NiiB Immunity+, contains the oral microbiome immunity formula SIM01.
The trial robustly demonstrated the exceptional effectiveness of SIM01 in alleviating post-COVID-19 conditions, sending a significant breakthrough and a glimmer of hope to the 65 million people around the world who have been deeply affected by the long COVID. It is widely recognized that post-COVID-19 symptoms exhibit significant interindividual variability, complexity, and long-term lifespan, posing a dual challenge to the patient’s physiological and psychological well-being. Given the current lack of targeted and effective therapies, this disease has emerged as one of the most daunting health challenges in the wake of the COVID-19 pandemic. In its August 2021 publication,
The Lancet mentioned that long COVID is the main challenge in modern medicine.
The oral formula of live microencapsulated bacteria SIM01, published in
Lancet infectious diseases this time it is G-NiiB’s flagship product GenieBiome. Multiple clinical studies have confirmed its effectiveness. This same study, known as the RECOVERY study, is the first global clinical research to demonstrate that SIM01 can improve the gut microbiota and effectively relieve post-COVID-19 symptoms, including fatigue, memory loss, difficulties concentration, gastrointestinal disorders and general discomfort. The study results highlight the interconnectedness of the “microbiome-gut-brain axis,” illustrating how probiotic metabolites absorbed from the gut can help improve brain function. This also highlights the potential of restoring a healthy gut microbiota as a novel intervention and strategy to treat post-COVID-19 neurological symptoms. The publication of the results of this research in
Lancet infectious diseases signifies an authoritative recognition of their scientific and pioneering property, as well as a strong affirmation of the possibility of SIM01 to improve post-COVID-19 symptoms and improve the overall immune performance of patients.
Ms. Rachel Fan, CEO of G-NiiB GenieBiomesaid: “The publication of the G-NiiB microbiome immunity formula trial, SIM01, in the medical journal
Lancet infectious diseases, undoubtedly constitutes a scientific feat and an important step for G-NiiB GenieBiome. It represents great recognition of the leadership, judgment and expertise of our founder and chief scientific advisor, demonstrating our leadership position and innovative capabilities in microbiome research. It also serves as a strong testimony to our professional competence and product quality, demonstrating that our core technology has received authoritative approval from the international medical community. This is considerable progress and an exceptional achievement for a pioneering company that wants to maintain a foothold in the microbiome field. We are immensely proud. »
Furthermore, “the practical significance of this study lies in proving the scientific efficacy and multiple feasibilities of SIM01, ushering in new avenues for microbiome research and human health exploration. From a societal perspective, G-NiiB’s microbiome immunity formula, SIM01, has the potential to provide a new choice for people suffering from long COVID while making a fundamental contribution to the fight against COVID -19 and other diseases. G-NiiB GenieBiome is committed to continued investment in innovative research and cutting-edge development, relentlessly striving to improve human health. and address various disease-related challenges.
Ms. Rachel Fan, CEO of G-NiiB GenieBiome, takes the clinical trial published in The Lancet Infectious Diseases as background.
Using advanced metagenomic sequencing data, patented artificial intelligence and microencapsulation technology, G-NiiB GenieBiome has introduced three patented oral microbiota formulations. These are SIM01, a microbiome precision immunity formula designed to strengthen the immune system; SMT04, a precision gut microbiome protection formula to preserve gut health; and SIM03, a children’s immunity formula with precision on the microbiome to develop diverse rainbow immunity. Clinical data from a renowned Hong Kong medical school supports these formulations. The team is currently researching the development of innovative formulations to treat and alleviate complex conditions such as fatty liver and adult eczema, with the aim of meeting the changing needs of the dietary supplement market.
Ms. Rachel Fan » added: “Our core team members excel in their respective fields. Our collective goal is to drive innovative transformation in human health through microbiome research. By leveraging the progress we have made in microbiota research, the team is working to significantly improve disease prevention. , diagnosis and treatment, sequentially accelerating the transition to a new era of microbiota-centered medicine.
https://www.g-niib.com
https://www.linkedin.com/company/geniebiome/
https://twitter.com/g_niib
https://www.facebook.com/gniib
https://www.instagram.com/g_niib/
Hashtag: #G-NiiBGenieBiome #SIM01 #LancetInfectiousDiseases #COVD-19 #RECOVERY #synbiotic #PACS
The issuer is solely responsible for the content of this announcement.
